AstraZeneca allowed COVID vaccine trials to resume – media

The United States has completed an investigation into the possible neurological effect in two participants of the vaccine trial.

In the United States, federal health authorities have allowed the British-Swedish pharmaceutical company AstraZeneca to resume trials of a coronavirus vaccine. This was reported by the Wall Street Journal on Friday, October 23, citing sources and documents at their disposal.

The FDA has completed an investigation into possible neurological effects in two participants in a vaccine trial.

According to the interlocutors of the publication, the regulator has not established a connection between the introduction of the vaccine and the appearance of symptoms, but cannot exclude it.

We will remember that Trump previously announced the appearance of a vaccine against COVID-19 as soon as possible. As soon as the vaccine against the new type of coronavirus infection is ready, the United States plans to distribute about 100 million doses.

Ukrainian vaccine against coronavirus. What is known

News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet